READ-ONLY DIGITIZATION RESULT
IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
Cancer Sci · 2026-Mar · PMID 41416818
Panel B提取完成待 EXE 对齐验证
OS
FIGURE 2 OS in Japanese patients with stage II–IIIA NSCLC by PD‐L1 status, a stage II–IIIA all‐randomized or stage IB–IIIA ITT populations. Kaplan–Meier estimates of OS in the (A) PD‐L1 TC ≥ 1%, (B) PD‐L1 TC 1%–49%, (C) PD‐L1 TC ≥ 50%, (D) stage II–IIIA all‐randomized, and (E) ITT populations are shown. a Evaluated by SP263 assay. BSC, best supportive care; CI, confidence interval; HR, hazard ratio; ITT, intention to treat; NE, not estimable; NSCLC, non‐small cell lung cancer; OS, overall survival; PD‐L1, programmed death 1 ligand; TC, tumor cell.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:24:33+00:00 |